Crogenic alloy screening Interim report

Evaluation of mechanical properties and fracture strength of aluminum alloys and stainless stee

Properties of cryogenically worked metals

A program was conducted to determine whether the mechanical properties of cryogenically worked 17-7PH stainless steel are suitable for service from ambient to cryogenic temperatures. It was determined that the stress corrosion resistance of the cryo-worked material is quite adequate for structural service. The tensile properties and fracture toughness at room temperature were comparable to titanium alloy 6Al-4V. However, at cryogenic temperatures, the properties were not sufficient to recommend consideration for structural service

Experimental study of pop-in behavior of surface flaw-type cracks Final report

Growth behavior of surface-flaw type cracks in titanium alloy

Atomic layer etching of SiO2 with Ar and CHF 3 plasmas: A self-limiting process for aspect ratio independent etching

With ever increasing demands on device patterning to achieve smaller critical dimensions, the need for precise, controllable atomic layer etching (ALE) is steadily increasing. In this work, a cyclical fluorocarbon/argon plasma is successfully used for patterning silicon oxide by ALE in a conventional inductively coupled plasma tool. The impact of plasma parameters and substrate electrode temperature on the etch performance is established. We achieve the self-limiting behavior of the etch process by modulating the substrate temperature. We find that at an electrode temperature of −10°C, etching stops after complete removal of the modified surface layer as the residual fluorine from the reactor chamber is minimized. Lastly, we demonstrate the ability to achieve independent etching, which establishes the potential of the developed cyclic ALE process for small scale device patterning

Determination of low-temperature fatigue properties of structural metal alloys Final report, Jul. 1964 - Aug. 1965

Fatigue testing and determination of low temperature properties of structural metal alloys - aluminum alloy, stainless steel, and nickel alloy

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy.

In part A of this study, patients were randomised to cohorts receiving darbepoetin alfa at doses of 0.5 to 8.0 m.c.g x kg(-1) x wk(-1) or to a control group receiving epoetin alfa at an initial dose of 150 U x kg(-1) three times weekly. In part B, the cohorts were darbepoetin alfa 3.0 to 9.0 m.c.g x kg(-1) every 2 weeks or epoetin alfa, initial dose 40 000 U x wk(-1). Safety was assessed by adverse events, changes in blood pressure, and formation of antibodies to darbepoetin alfa. Efficacy was assessed by several haematologic endpoints, including change in haemoglobin from baseline. The adverse event profile of darbepoetin alfa was similar to that of epoetin alfa. No relationship between the rapidity of haemoglobin response and any adverse event was observed. No antibodies to darbepoetin alfa were detected. Higher doses of darbepoetin alfa increased the proportion of patients with a haemoglobin response and decreased the median time to response. The overall dose of darbepoetin alfa required to produce a mean increase in haemoglobin does not increase when the dosing interval is increased from 1 to 2 weeks. Therapy with darbepoetin alfa is safe and effective in producing a dose-related increase in haemoglobin levels in patients with cancer receiving chemotherapy